Navigation Links
NewBridge Pharmaceuticals Announces Licensing of Pylera(R) for Middle East, Africa, Turkey & Caspian Region
Date:7/22/2009

any, a San Francisco based Life Science Venture Capital, Private Equity, Merchant Banking and Media firm. NewBridge Pharmaceuticals is uniquely positioned as the partner of choice for pharmaceutical, biotechnology and device companies seeking to capture value from their products in these high growth emerging markets.

About Axcan Pharma

Axcan Pharma is a privately-held, leading specialty pharmaceutical company that develops and markets a wide range of products to treat gastrointestinal diseases and disorders, such as inflammatory bowel disease, cholestatic liver diseases, irritable bowel syndrome, and complications related to pancreatic insufficiency. Axcan's products are marketed by its own dedicated and specialized sales forces both in North America and the European Union. The company also markets its products in more than 40 countries through a global network of local partners.

www.axcan.com


'/>"/>
SOURCE NewBridge Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Newbridge Securities Corporation Forms BioVentures Division
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... April 28, 2015 The Pistoia Alliance, ... work together to lower barriers to innovation in R&D, ... project. , The Ontologies Mapping project has been ... practices for ontology management in life sciences R&D. The ... of standardized guidelines, tools and services to enable the ...
(Date:4/28/2015)... According to a 2013 report from ... medical treatment from burn injuries per year. Despite several ... formation of scars with subsequent contractures remains a major ... there is no adequate treatment. Contractures are a permanent ... can cause permanent deformity. , Synedgen has developed ...
(Date:4/28/2015)... 28, 2015 Reproductive endocrinologist Dr. Kaylen ... 7 couples battling infertility in this country, testified on behalf ... as the first state in the nation to consider creating ... to couples who desire to receive them. , Infertility affects ... that infertility is one of the few medical diseases that ...
(Date:4/27/2015)... HEIDELBERG , Alemania, April 27, 2015 ... patente para un nuevo receptor utilizando tecnología de descubrimiento ... no cubierta en el tratamiento de millones de pacientes ... anunciado hoy que ha recibido una patente en Europa ... el descubrimiento de Molecular Health de que EPHB4 es ...
Breaking Biology Technology:Pistoia Alliance Announces Start of Ontologies Mapping Project 2Synedgen Burn Treatment Results Presented at Premier Wound Conference 2Synedgen Burn Treatment Results Presented at Premier Wound Conference 3Texas Fertility Center Supports a Groundbreaking HB1145 that Facilitates Embryo Donation in Texas 2Texas Fertility Center Supports a Groundbreaking HB1145 that Facilitates Embryo Donation in Texas 3Molecular Health obtiene la patente para un nuevo receptor 2Molecular Health obtiene la patente para un nuevo receptor 3
... 6 , 3Q09 Corporate Highlights: ... to Astellas Pharma Europe Ltd. Made significant progress ... VP Sales; Senior Director, Marketing; and Director, Commercial Operations ... Committee chairman , Upcoming 2009 Milestones: ...
... Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced ... REOLYSIN(R) in patients with sarcomas metastatic to the lung ... Tissue Oncology Society Meeting held in Miami Beach, Florida, ... "A Phase II Study of Intravenous REOLYSIN (Wild-type Reovirus) ...
... ... place on February 22-24, 2010 in Philadelphia, has been announced. At this three day ... to share their experiences. , ... Minneapolis, MN (PRWEB) November 6, 2009 -- The agenda for Arrowhead’s ...
Cached Biology Technology:NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3
(Date:4/14/2015)... OXFORD, Conn. , April 14, 2015 ... "Company"), a biometric authentication company focused on the growing ... has been nominated for the 2015 New York Design ... The Design100, New York City Design Awards are ... are based on over 2,500 ratings from the marketplace, ...
(Date:4/13/2015)... -- higi, a leading cloud-based consumer engagement platform that provides ... their communities around health and wellness, announced today the ... ... convenient vehicle to receive validated health information from consumers. ... API will allow higi,s trusted partners, on a user ...
(Date:4/9/2015)... Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the third quarter of ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-438-5524 (conference ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2
... decades, crop breeders have increasingly relied on the wild and ... resistance, drought tolerance, and other traits. But just like all ... at risk of decline and extinction due to habitat loss, ... two speakers will describe the latest efforts to identify and ...
... Ohio The discovery of genetic differences affecting up ... guesswork out of prescribing the correct dose of 25 ... The scientists found two genetic variants that alter ... or metabolizing, drugs ranging from the painkiller codeine to ...
... 10 per cent of the UK is left handed ... world. But why exactly someone is left or right handed ... Nottingham,s Professor John Armour and Dr Angus Davison, in collaboration ... genetic determinant, in influencing handedness. The researchers conducted ...
Cached Biology News:Protecting the weedy and wild kin of globally important crops 2New genetic discovery could reduce the guesswork in drug dosing 2New genetic discovery could reduce the guesswork in drug dosing 3New genetic discovery could reduce the guesswork in drug dosing 4What makes us left or right handed? New study rules out strong genetic factors 2